Carisma Therapeutics (CARM) Competitors $0.44 -0.02 (-3.46%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends CARM vs. ANL, AVTE, RANI, PMVP, CLSD, AVTX, ANIX, UNCY, GALT, and CTMXShould you be buying Carisma Therapeutics stock or one of its competitors? The main competitors of Carisma Therapeutics include Adlai Nortye (ANL), Aerovate Therapeutics (AVTE), Rani Therapeutics (RANI), PMV Pharmaceuticals (PMVP), Clearside Biomedical (CLSD), Avalo Therapeutics (AVTX), Anixa Biosciences (ANIX), Unicycive Therapeutics (UNCY), Galectin Therapeutics (GALT), and CytomX Therapeutics (CTMX). These companies are all part of the "pharmaceutical products" industry. Carisma Therapeutics vs. Adlai Nortye Aerovate Therapeutics Rani Therapeutics PMV Pharmaceuticals Clearside Biomedical Avalo Therapeutics Anixa Biosciences Unicycive Therapeutics Galectin Therapeutics CytomX Therapeutics Carisma Therapeutics (NASDAQ:CARM) and Adlai Nortye (NASDAQ:ANL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, community ranking, risk, media sentiment and profitability. Do analysts rate CARM or ANL? Carisma Therapeutics currently has a consensus target price of $4.94, indicating a potential upside of 1,020.94%. Adlai Nortye has a consensus target price of $9.00, indicating a potential upside of 326.34%. Given Carisma Therapeutics' higher possible upside, analysts clearly believe Carisma Therapeutics is more favorable than Adlai Nortye.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.43Adlai Nortye 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, CARM or ANL? Carisma Therapeutics has a beta of 1.56, suggesting that its stock price is 56% more volatile than the S&P 500. Comparatively, Adlai Nortye has a beta of -1.38, suggesting that its stock price is 238% less volatile than the S&P 500. Which has preferable valuation and earnings, CARM or ANL? Carisma Therapeutics has higher revenue and earnings than Adlai Nortye. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCarisma Therapeutics$14.92M1.23-$86.88M-$1.56-0.28Adlai Nortye$5M15.58-$104.87MN/AN/A Does the MarketBeat Community believe in CARM or ANL? Carisma Therapeutics received 9 more outperform votes than Adlai Nortye when rated by MarketBeat users. However, 100.00% of users gave Adlai Nortye an outperform vote while only 77.27% of users gave Carisma Therapeutics an outperform vote. CompanyUnderperformOutperformCarisma TherapeuticsOutperform Votes1777.27% Underperform Votes522.73% Adlai NortyeOutperform Votes8100.00% Underperform VotesNo Votes Is CARM or ANL more profitable? Adlai Nortye has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -314.78%. Adlai Nortye's return on equity of 0.00% beat Carisma Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Carisma Therapeutics-314.78% -957.20% -96.39% Adlai Nortye N/A N/A N/A Do insiders & institutionals have more ownership in CARM or ANL? 44.3% of Carisma Therapeutics shares are held by institutional investors. Comparatively, 35.2% of Adlai Nortye shares are held by institutional investors. 12.6% of Carisma Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media prefer CARM or ANL? In the previous week, Carisma Therapeutics had 1 more articles in the media than Adlai Nortye. MarketBeat recorded 2 mentions for Carisma Therapeutics and 1 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 0.47 beat Carisma Therapeutics' score of 0.25 indicating that Adlai Nortye is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Carisma Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adlai Nortye 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryCarisma Therapeutics beats Adlai Nortye on 9 of the 17 factors compared between the two stocks. Get Carisma Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CARM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CARM vs. The Competition Export to ExcelMetricCarisma TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.40M$6.22B$5.21B$9.14BDividend YieldN/A2.94%5.13%4.02%P/E Ratio-0.289.8789.3417.36Price / Sales1.23309.211,240.0477.11Price / CashN/A61.4443.7535.97Price / Book0.676.055.314.79Net Income-$86.88M$154.90M$122.54M$225.00M7 Day Performance0.62%-0.32%0.59%2.62%1 Month Performance5.46%0.43%2.55%3.81%1 Year Performance-80.76%3.08%25.29%20.10% Carisma Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CARMCarisma Therapeutics3.9616 of 5 stars$0.44-3.5%$4.94+1,020.9%-80.8%$18.40M$14.92M-0.2820Short Interest ↓ANLAdlai Nortye1.653 of 5 stars$1.98-0.5%$9.00+354.5%-76.5%$73.06M$5M0.00127Positive NewsGap UpAVTEAerovate Therapeutics1.0561 of 5 stars$2.52-1.2%$2.25-10.7%-87.3%$72.77MN/A-0.8420Positive NewsRANIRani Therapeutics3.6354 of 5 stars$1.26+0.8%$11.71+829.7%-62.0%$72.18M$2.72M-1.19110Positive NewsPMVPPMV Pharmaceuticals2.2488 of 5 stars$1.39-4.8%$5.50+295.7%-14.9%$71.93MN/A-1.3950Positive NewsCLSDClearside Biomedical3.2171 of 5 stars$0.94-4.0%$5.33+467.1%-27.9%$71.32M$7.70M-2.0930Positive NewsAVTXAvalo Therapeutics4.0397 of 5 stars$6.84-2.3%$40.00+484.8%+60.3%$71.10M$820,000.000.0040Short Interest ↓ANIXAnixa Biosciences3.3574 of 5 stars$2.20-2.2%$8.50+286.4%-51.4%$70.79M$210,000.00-5.645UNCYUnicycive Therapeutics3.0371 of 5 stars$0.68+2.0%$5.50+711.2%-28.4%$70.37M$680,000.00-0.709GALTGalectin Therapeutics2.1349 of 5 stars$1.12+1.8%$11.00+882.7%-29.1%$70.26MN/A-1.539Positive NewsCTMXCytomX Therapeutics4.6352 of 5 stars$0.89+1.1%$5.77+548.5%-48.5%$69.66M$126.62M5.24170 Related Companies and Tools Related Companies Adlai Nortye Alternatives Aerovate Therapeutics Alternatives Rani Therapeutics Alternatives PMV Pharmaceuticals Alternatives Clearside Biomedical Alternatives Avalo Therapeutics Alternatives Anixa Biosciences Alternatives Unicycive Therapeutics Alternatives Galectin Therapeutics Alternatives CytomX Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CARM) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carisma Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Carisma Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CARM Stock Alerts